Kirsten Boonstra1, Robin Bokelaar1, Paul H Stadhouders2, Hans A Tuynman3, Alexander C Poen4, Karin M van Nieuwkerk5, Ellen M Witteman6, Dörte Hamann7, Ben J Witteman8, Ulrich Beuers1, Cyriel Y Ponsioen9. 1. Department of Gastroenterology and Hepatology, Academic Medical Center, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands. 2. Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands. 3. Department of Gastroenterology and Hepatology, Medical Center Alkmaar, Alkmaar, The Netherlands. 4. Department of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands. 5. Department of Gastroenterology and Hepatology, VU Medical Center, Amsterdam, The Netherlands. 6. Department of Gastroenterology and Hepatology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 7. Diagnostic Services, Sanquin Research, Amsterdam, The Netherlands. 8. Department of Gastroenterology and Hepatology, Gelderse Vallei Hospital, Ede, The Netherlands. 9. Department of Gastroenterology and Hepatology, Academic Medical Center, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands. c.y.ponsioen@amc.uva.nl.
Abstract
BACKGROUND AND AIMS: The natural history of primary biliary cirrhosis (PBC) has so far mainly been studied in tertiary referral centres. The aim of the present investigation was to describe the natural history of PBC in a large population-based cohort in order to identify risk factors for development of malignancies and disease progression. METHODS: Four independent hospital databases were searched in 44 hospitals in a geographically defined area, after which all medical records were evaluated on site. In addition, PBC registries in the three liver transplant centers were checked for missed referrals from the area of interest. RESULTS: In total, 992 cases fulfilled the inclusion criteria. The median follow-up was 73 months (range 0-434). Mortality was similar to the age- and gender matched population (SMR 1.1; 95 % CI 0.9-1.4). Male gender, smoking, and elevated bilirubin, decreased albumin, and elevated AST at time of diagnosis, were associated with an increased risk for the combined end point PBC-related death or liver transplantation. In total, 133 (13 %) patients developed one or more malignancies (SIR 1.5; 95 % CI 1.1-1.9). There was a ninefold increased risk of developing hepatobiliary malignancies (SIR 9.4; 95 % CI 3.04-21.8), a fivefold increased risk of developing urinary bladder cancer (SIR 5.0; 95 % CI 1.6-11.6), and a 1.8-fold increased risk of developing breast cancer (SIR 1.8; 95 % CI 1.08-2.81). CONCLUSION: PBC is associated with an increased risk of hepatobiliary, bladder and breast cancer. Still, survival-under treatment with ursodeoxycholic acid (UDCA)-was comparable to the general population in this population-based study.
BACKGROUND AND AIMS: The natural history of primary biliary cirrhosis (PBC) has so far mainly been studied in tertiary referral centres. The aim of the present investigation was to describe the natural history of PBC in a large population-based cohort in order to identify risk factors for development of malignancies and disease progression. METHODS: Four independent hospital databases were searched in 44 hospitals in a geographically defined area, after which all medical records were evaluated on site. In addition, PBC registries in the three liver transplant centers were checked for missed referrals from the area of interest. RESULTS: In total, 992 cases fulfilled the inclusion criteria. The median follow-up was 73 months (range 0-434). Mortality was similar to the age- and gender matched population (SMR 1.1; 95 % CI 0.9-1.4). Male gender, smoking, and elevated bilirubin, decreased albumin, and elevated AST at time of diagnosis, were associated with an increased risk for the combined end point PBC-related death or liver transplantation. In total, 133 (13 %) patients developed one or more malignancies (SIR 1.5; 95 % CI 1.1-1.9). There was a ninefold increased risk of developing hepatobiliary malignancies (SIR 9.4; 95 % CI 3.04-21.8), a fivefold increased risk of developing urinary bladder cancer (SIR 5.0; 95 % CI 1.6-11.6), and a 1.8-fold increased risk of developing breast cancer (SIR 1.8; 95 % CI 1.08-2.81). CONCLUSION: PBC is associated with an increased risk of hepatobiliary, bladder and breast cancer. Still, survival-under treatment with ursodeoxycholic acid (UDCA)-was comparable to the general population in this population-based study.
Authors: Edith M M Kuiper; Bettina E Hansen; Rob P R Adang; Carin M J van Nieuwkerk; Robin Timmer; Joost P H Drenth; Piet Spoelstra; Hans T Brouwer; Johan P H Kuyvenhoven; Henk R van Buuren Journal: Eur J Gastroenterol Hepatol Date: 2010-12 Impact factor: 2.566
Authors: M Eric Gershwin; Carlo Selmi; Howard J Worman; Ellen B Gold; Mitchell Watnik; Jessica Utts; Keith D Lindor; Marshall M Kaplan; John M Vierling Journal: Hepatology Date: 2005-11 Impact factor: 17.425
Authors: P A Murtaugh; E R Dickson; G M Van Dam; M Malinchoc; P M Grambsch; A L Langworthy; C H Gips Journal: Hepatology Date: 1994-07 Impact factor: 17.425
Authors: Edith M M Kuiper; Bettina E Hansen; Herold J Metselaar; Robert A de Man; Els B Haagsma; Bart van Hoek; Henk R van Buuren Journal: BMC Gastroenterol Date: 2010-12-20 Impact factor: 3.067
Authors: Valery Hrad; Yoftahe Abebe; Syed Haris Ali; Jared Velgersdyk; Mohammed Al Hallak; Mohamad Imam Journal: Gastroenterol Res Pract Date: 2016-06-19 Impact factor: 2.260
Authors: T K Felder; E Aigner; S Zandanell; M Strasser; A Feldman; J Tevini; G Strebinger; D Niederseer; G Pohla-Gubo; U Huber-Schönauer; S Ruhaltinger; B Paulweber; C Datz Journal: J Intern Med Date: 2019-12-04 Impact factor: 8.989
Authors: Victoria L Brun; Amanda F Corbel; Ann W Hsing; Troy J Kemp; Alison L Van Dyke; Allan Hildesheim; Bin Zhu; Yu-Tang Gao; Ligia A Pinto; Jill Koshiol Journal: Sci Rep Date: 2021-06-28 Impact factor: 4.996